← Russell 3000 cross-section

STTK Shattuck Labs, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$786m
Revenue TTM
$1m
Net income TTM
$-53m
Free cash flow
Composite score
Sector rank
#2164

Valuation

P / E
EV / EBITDA
EV / sales
723.0
FCF yield
Earnings yield vs 10-yr
-11.42pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-5,256.8%
EBITDA margin
-5,222.2%
ROE
-24.9%
ROIC
-37.7%
Revenue growth
-66.6%

Insider activity, last 90 days

Net open-market
$-0.13m
Buyers
1
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Pursuant to the Kayak Agreement, the Company is also eligible to receive future payments contingent upon the achievement of specified development, regulatory, and commercial milestones of up to $ 86.0 million, and tiered royalties on net sales of any commercialized products subject to the Kayak Agreement in the low single digits. The Sales Agent is generally entitled to compensation at a commission equal to up to 3 % of the aggregate gross sales price per share sold under the Sales Agreement. …Shattuck Labs, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →